Once-weekly exenatide as a treatment for Type 2 diabetes

Keyphrases

• Type 2 Diabetes Mellitus (T2DM) 100%
• Exenatide Once Weekly 100%
• Hemoglobin A1c (HbA1c) 66%
• Vascular Complications 66%
• Disease Progression 33%
• United States 33%
• Progressive Disease 33%
• Glucose Control 33%
• Combination Therapy 33%
• Pharmacological Therapy 33%
• A1 Receptor 33%
• Receptor Agonist 33%
• Pharmacoeconomic Analysis 33%
• Second-line Agents 33%
• Glucagon-like 33%
• Clinical Observational Study 33%
• Control Targets 33%
• Hypoglycemia Risk 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Non Insulin Dependent Diabetes Mellitus 100%
• Exendin 4 100%
• Disease 66%
• Hemoglobin A1c 66%
• Clinical Trial 33%
• Combination Therapy 33%
• Hypoglycemia 33%
• Pharmacoeconomics 33%
• Glucagon Like Peptide 1 Receptor Agonist 33%
• Observational Study 33%